Analysis And Perspectives

Currently, more than 70 companies are evaluating 235+ AAV vectors in gene therapy at different stages to improve the therapeutics segment.

Interoperability solutions in healthcare are improving the patient experience by streamlining care delivery. Major companies in the market

The expected launch of newly approved Molluscum Contagiosum therapies such as VP-102 and SB206 are expected to drive the therapeutics segment in the coming years.

Globally, Telepsychiatry demand is rising at an immense pace. Key companies are working in the market to fulfill their needs. Due to various benefits, the market is

The Dystrophic Epidermolysis Bullosa treatment market has a promising outlook. Various gene therapies in different stages are in the pipeline.

Currently, the PML Therapeutics pipeline mainly comprises early phase assets. Limited companies are investigating in PML treatment options.

The role of Artificial Intelligence in Mental Health is growing at an immense pace. The application of AI is providing immense benefit to user

Several late-stage therapies developed by leading players for generalized myasthenia gravis treatment are expected to enter the therapeutics market

Currently, there is no effective curative ADPKD treatment. However, leading companies in the therapeutics segment are evaluating novel drugs.

Bronchopulmonary Dysplasia Treatment Market is expected to showcase massive growth as several pharma companies are developing therapies